29976-54-3

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-oxopiperidine-1-carboxylate is used as an intermediate for the synthesis of various pharmaceuticals. Its unique structure and reactivity make it suitable for the development of new drugs and medicinal compounds, contributing to the advancement of healthcare and treatment options.
Used in Agrochemical Industry:
In the agrochemical sector, methyl 4-oxopiperidine-1-carboxylate is utilized as an intermediate in the production of agrochemicals. Its role in the synthesis of these compounds helps to improve crop protection, yield, and overall agricultural productivity.
Used in Organic Synthesis:
Methyl 4-oxopiperidine-1-carboxylate is employed as a reagent in organic synthesis. Its chemical properties allow it to participate in various reactions, facilitating the creation of new organic compounds and contributing to the expansion of organic chemistry knowledge and applications.
Used in Chemical Compound Preparation:
As a building block, methyl 4-oxopiperidine-1-carboxylate is used in the preparation of a wide range of chemical compounds. Its versatility and compatibility with other chemical entities enable the synthesis of diverse products, further broadening its applications across various industries.

InChI:InChI=1/C7H11NO3/c1-11-7(10)8-4-2-6(9)3-5-8/h2-5H2,1H3

Upstream product

• 41979-39-9 4-piperidone hydrochloride 
• 79-22-1 methyl chloroformate 
• 41661-47-6 piperidin-4-one 

Downstream Products

• 76508-54-8 1-methoxycarbonyl-4-cyano-4-aminopiperidine 
• 1078691-79-8 methyl 2-amino-3-(3,4,5-trimethoxybenzoyl)-4,7-dihydrothieno[2,3-c]pyridine-6(5H)-carboxylate 
• 75250-52-1 4-hydroxy-piperidine-1-carboxylic acid methyl ester 
• 1228557-61-6 (3E,5E)-methyl 3,5-bis(3-nitrobenzylidene)-4-oxopiperidine-1-carboxylate 
• 335459-95-5 C₇H₁₁NO₄ 
• 76508-55-9 4-aminopiperidine-4-carboxylic acid hydrobromide 
• 491875-47-9 4-[bis-(4-methoxy-3-methoxycarbonyl-5-methyl-phenyl)-methylene]-piperidine-1-carboxylic acid methyl ester 
• 491875-50-4 4-[bis-(3-chloro-4-methoxy-5-methoxycarbonyl-phenyl)-methylene]-piperidine-1-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Total Synthesis Provides Strong Evidence: Xestocyclamine A is the Enantiomer of Ingenamine

Xestocyclamine A ((-)-1) is featured prominently in a biosynthesis pathway leading to a large family of polycyclic alkaloids. The first total synthesis now proves that the structure of this compound had originally been misassigned. The route to (-)-1 is based on a double Michael addition for the formation of the bridged diazadecalin core and a palladium-catalyzed decarboxylative allylation to install the quaternary bridgehead center. Ring-closing alkyne metathesis allowed a 13-membered cycloalkyne to be forged, which was selectively reduced during an involved sequence of hydroboration/selective protodeborylation/alkyl-Suzuki coupling used to close the 11-membered ring. Crystallographic data prove the identity of synthetic (-)-1 with nominal xestocyclamine, but the spectra differ from those of the authentic alkaloid. To clarify the point, the synthesis was redirected toward ingenamine (3), which is supposedly a positional isomer of 1. The recorded data confirm the assignment of this particular natural product and strongly suggest that xestocyclamine A is in fact the enantiomer of ingenamine (+)-3.

Electrophotochemical Ring-Opening Bromination oftert-Cycloalkanols

An electrophotochemical ring-opening bromination of unstrainedtert-cycloalkanols has been developed. This electrophotochemical method enables the oxidative transformation of cycloalkanols with 5- to 7-membered rings into synthetically useful ω-bromoketones without the use of chemical oxidants or transition-metal catalysts. Alkoxy radical species would be key intermediates in the present transformation, which generate through homolysis of the O-Br bond in hypobromite intermediates under visible light irradiation.

ANTI-BACTERIAL COMPOUNDS

A compound of Formula (II): for use in the prevention or treatment of a bacterial infection.

THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS

The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer

Synthesis of substituted diarylmethylenepiperidines (DAMPs), a novel class of anti-HIV agents.

Substituted diarylmethylenepiperidines (DAMPs) were synthesized as conformationally restricted analogues of the alkenyldiarylmethane (ADAM) class of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Although, like the ADAMs, the DAMPs were found to inhibit the cytopathic effect of HIV-1(RF) in CEM-SS cells, they were completely inactive as inhibitors of HIV-1 reverse transcriptase. The DAMPs were assessed for inhibition of HIV attachment and fusion. DAMP was active in both assays with IC(50) values of 26.5 microM (TI 3.8) and 12.1 microM (TI: >8), respectively. DAMP also inhibited HIV fusion with an IC(50 )12.8 microM (TI: >6), but not virus attachment. However, attempts to verify inhibition of virus attachment and fusion as antiviral targets using time-of-addition experiments failed to confirm these observations, and instead identified an antiviral target occurring after completion of reverse transcription. DAMPs, and were found to inhibit virus replication if added 8 h post virus exposure, and DAMP was equipotent at inhibition of virus replication if added 24 h after virus addition. DAMPs, and did not inhibit virus replication in TNF-alpha induced latently infected U1 cells, a model for post-integrative antiviral targets. When tested in both 3' end-processing and strand-transfer assays in the presence of HIV-1 integrase, none of the DAMPs showed any inhibitory activity, indicating that HIV-1 integrase is not involved in the mechanism of the antiviral action. Thus, the DAMPs are novel conformationally restricted analogues of the previously published ADAM series with an unidentified antiviral target bounded by the completion of reverse transcription and virus integration.

GABA agonists. Synthesis and structure-activity studies on analogues of isoguvacine and THIP

A series of analogues of the specific GABA receptor agonists isoguvacine, isonipecotic acid, and THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol) have been synthesized and tested as inhibitors of the binding of 3H-GABA to GABA receptor sites on rat brain membranes in vitro. Introduction of a hydroxy group into the 3- or 4-position of isonipecotic acid results in compounds with considerably reduced receptor affinity. The 7-membered ring analogues of isoguvacine and isonipecotic acid are more than two orders of magnitude weaker than the parent compounds. Replacement of the 3-isoxazolol unit of THIP by related heterocyclic rings also result in dramatic loss of activity. Thus iso-THIP (4,5,6,7-tetrahydroisoxazolo[3,4-c]pyridin-3-ol) is a weak inhibitor of 3H-GABA binding, whereas the 3-pyrazolol THIP analogues are inactive.

3-Hydrazino-cycloalkyl[c]pyridazines

This invention provides aminopyridazine derivatives of formula I, SPC1 wherein R1 is amino, or an EQU1 group, wherein each of R3 and R4 is alkyl of 1 to 4 carbon atoms, or R3 and R4 together with the carbon atom to which they are bound, form a cycloalkylidene radical of 5 to 12 carbon atoms, R2 is hydrogen or methyl, A is a --(CH2)n -- group, Wherein n is 0 or an integer from 1 to 7, or an >N--CO--R5 group, Wherein R5 is alkyl or alkenyl of 1 to 16 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, 1-adamantyl, or a --(CH2)m --R6 group, Wherein m is 0 or an integer from 1 to 4, and R6 is phenyl; phenyl monosubstituted by fluorine, chlorine, bromine, alkyl or alkoxy of 1 to 4 carbon atoms, alkylmercapto of 1 to 4 carbon atoms, or phenyl; phenyl substituted by two or three substituents of the group chlorine, alkyl or alkoxy of 1 to 4 carbon atoms; diphenylmethyl, the phenyl rings of which may be monosubstituted by fluorine, chlorine, bromine, alkyl or alkoxy of 1 to 4 carbon atoms; or naphthyl, Or an --OR7 group, Wherein R7 is alkyl or alkenyl of 1 to 4 carbon atoms, or phenyl, phenylalkyl or phenylalkenyl which may be monosubstituted on the phenyl ring by chlorine, alkyl or alkoxy of 1 to 4 carbon atoms, and in which the alkylene or alkenylene chain is of 1 to 4 carbon atoms, And R8 and R9 are each hydrogen or alkyl of 1 to 4 carbon atoms, And acid addition salts thereof. The invention also provides processes for the production of said compounds. Said compounds and pharmaceutically acceptable acid addition salts thereof are useful as antihypertensive agents.